BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11781254)

  • 1. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.
    Stepkowski SM; Erwin-Cohen RA; Behbod F; Wang ME; Qu X; Tejpal N; Nagy ZS; Kahan BD; Kirken RA
    Blood; 2002 Jan; 99(2):680-9. PubMed ID: 11781254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
    Behbod F; Erwin-Cohen RA; Wang ME; Trawick BW; Qu X; Verani R; Kahan BD; Stepkowski SM; Kirken RA
    J Immunol; 2001 Mar; 166(6):3724-32. PubMed ID: 11238613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection.
    Stepkowski SM; Nagy ZS; Wang ME; Behbod F; Erwin-Cohen R; Kahan BD; Kirken RA
    Transplant Proc; 2001; 33(7-8):3272-3. PubMed ID: 11750401
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection.
    Wang M; Kirken R; Behbod F; Erwin-Cohen R; Stepkowski SM; Kahan BD
    Transplant Proc; 2001; 33(1-2):201. PubMed ID: 11266779
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
    Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
    J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
    Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
    J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase 3: a novel target for selective transplant immunosupression.
    Podder H; Kahan BD
    Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
    Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts.
    Kirken RA; Erwin-Cohen R; Behbod F; Wang M; Stepkowski SM; Kahan BD
    Transplant Proc; 2001; 33(1-2):95. PubMed ID: 11266723
    [No Abstract]   [Full Text] [Related]  

  • 10. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities.
    Stepkowski SM; Kao J; Wang ME; Tejpal N; Podder H; Furian L; Dimmock J; Jha A; Das U; Kahan BD; Kirken RA
    J Immunol; 2005 Oct; 175(7):4236-46. PubMed ID: 16177063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway.
    Li WQ; Dehnade F; Zafarullah M
    J Immunol; 2001 Mar; 166(5):3491-8. PubMed ID: 11207308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
    Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
    Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
    Deuse T; Velotta JB; Hoyt G; Govaert JA; Taylor V; Masuda E; Herlaar E; Park G; Carroll D; Pelletier MP; Robbins RC; Schrepfer S
    Transplantation; 2008 Mar; 85(6):885-92. PubMed ID: 18360272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C.
    Fernández L; Flores-Morales A; Lahuna O; Sliva D; Norstedt G; Haldosén LA; Mode A; Gustafsson JA
    Endocrinology; 1998 Apr; 139(4):1815-24. PubMed ID: 9528967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.
    Wang ME; Tejpal N; Qu X; Yu J; Okamoto M; Stepkowski SM; Kahan BD
    Transplantation; 1998 Apr; 65(7):899-905. PubMed ID: 9565092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation.
    Mortellaro A; Songia S; Gnocchi P; Ferrari M; Fornasiero C; D'Alessio R; Isetta A; Colotta F; Golay J
    J Immunol; 1999 Jun; 162(12):7102-9. PubMed ID: 10358154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.
    Johnston JA; Bacon CM; Finbloom DS; Rees RC; Kaplan D; Shibuya K; Ortaldo JR; Gupta S; Chen YQ; Giri JD
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8705-9. PubMed ID: 7568001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
    Säemann MD; Zeyda M; Diakos C; Szekeres A; Böhmig GA; Kelemen P; Parolini O; Stockinger H; Prieschl EE; Stulnig TM; Baumruker T; Zlabinger GJ
    Transplantation; 2003 Jun; 75(11):1864-72. PubMed ID: 12811247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRL-induced ERalpha gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase.
    Frasor J; Barkai U; Zhong L; Fazleabas AT; Gibori G
    Mol Endocrinol; 2001 Nov; 15(11):1941-52. PubMed ID: 11682625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
    Saharinen P; Silvennoinen O
    J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.